Arcturus Therapeutics Holdings Financial Statements (ARCT)
|
|
|
|
Report date
|
|
|
01.03.2021 |
01.03.2022 |
29.03.2023 |
31.12.2023 |
14.03.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
9.54 |
12.4 |
205.8 |
169.9 |
157.7 |
|
148.5 |
|
Operating Income, bln rub |
|
|
-71.5 |
-202.9 |
12.2 |
-75.1 |
-78.2 |
|
-54.9 |
|
EBITDA, bln rub |
? |
|
-70.6 |
-201.7 |
13.7 |
-75.1 |
-24.2 |
|
-59.3 |
|
Net profit, bln rub |
? |
|
-71.4 |
-206.9 |
9.35 |
-26.6 |
-29.7 |
|
-59.5 |
|
|
OCF, bln rub |
? |
|
-42.9 |
-135.0 |
32.0 |
|
-18.1 |
|
-60.0 |
|
CAPEX, bln rub |
? |
|
1.74 |
3.41 |
7.73 |
|
2.90 |
|
1.96 |
|
FCF, bln rub |
? |
|
-44.6 |
-138.4 |
24.3 |
|
-21.0 |
|
-60.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
81.1 |
215.2 |
193.6 |
245.0 |
236.0 |
|
198.8 |
|
Cost of production, bln rub |
|
|
55.9 |
171.9 |
143.1 |
0.000 |
2.96 |
|
7.13 |
|
R&D, bln rub |
|
|
57.8 |
173.8 |
147.8 |
192.1 |
192.1 |
|
155.9 |
|
Interest expenses, bln rub |
|
|
0.361 |
2.67 |
0.420 |
0.000 |
0.767 |
|
0.004 |
|
|
Assets, bln rub |
|
|
476.5 |
392.8 |
450.4 |
429.4 |
429.4 |
|
370.7 |
|
Net Assets, bln rub |
? |
|
396.6 |
228.2 |
270.3 |
281.6 |
278.5 |
|
261.9 |
|
Debt, bln rub |
|
|
17.9 |
67.6 |
90.9 |
25.9 |
30.2 |
|
26.0 |
|
Cash, bln rub |
|
|
462.9 |
370.5 |
391.9 |
347.0 |
292.0 |
|
237.2 |
|
Net debt, bln rub |
|
|
-445.0 |
-302.9 |
-301.0 |
-321.1 |
-261.8 |
|
-211.2 |
|
|
Ordinary share price, rub |
|
|
43.4 |
37.0 |
17.0 |
31.5 |
31.5 |
|
19.0 |
|
Number of ordinary shares, mln |
|
|
20.3 |
26.3 |
26.4 |
26.6 |
26.6 |
|
27.1 |
|
|
Market cap, bln rub |
|
|
881 |
974 |
449 |
840 |
840 |
|
514 |
|
EV, bln rub |
? |
|
436 |
671 |
147 |
518 |
578 |
|
302 |
|
Book value, bln rub |
|
|
397 |
228 |
270 |
282 |
279 |
|
262 |
|
|
EPS, rub |
? |
|
-3.51 |
-7.86 |
0.35 |
-1.00 |
-1.12 |
|
-2.20 |
|
FCF/share, rub |
|
|
-2.20 |
-5.26 |
0.92 |
0.00 |
-0.79 |
|
-2.25 |
|
BV/share, rub |
|
|
19.5 |
8.67 |
10.2 |
10.6 |
10.5 |
|
9.68 |
|
|
EBITDA margin, % |
? |
|
-740.6% |
-1 632% |
6.66% |
-44.2% |
-15.3% |
|
-40.0% |
|
Net margin, % |
? |
|
-748.1% |
-1 674% |
4.54% |
-15.6% |
-18.8% |
|
-40.1% |
|
FCF yield, % |
? |
|
-5.06% |
-14.2% |
5.41% |
0.00% |
-2.50% |
|
-11.8% |
|
ROE, % |
? |
|
-18.0% |
-90.6% |
3.46% |
-9.44% |
-10.7% |
|
-22.7% |
|
ROA, % |
? |
|
-15.0% |
-52.7% |
2.08% |
-6.19% |
-6.92% |
|
-16.1% |
|
|
P/E |
? |
|
-12.3 |
-4.71 |
48.0 |
-31.6 |
-28.2 |
|
-8.63 |
|
P/FCF |
|
|
-19.7 |
-7.04 |
18.5 |
|
-40.0 |
|
-8.44 |
|
P/S |
? |
|
92.3 |
78.8 |
2.18 |
4.94 |
5.32 |
|
3.46 |
|
P/BV |
? |
|
2.22 |
4.27 |
1.66 |
2.98 |
3.01 |
|
1.96 |
|
EV/EBITDA |
? |
|
-6.17 |
-3.33 |
10.8 |
-6.91 |
-23.9 |
|
-5.10 |
|
Debt/EBITDA |
|
|
6.30 |
1.50 |
-22.0 |
4.28 |
10.8 |
|
3.56 |
|
|
R&D/CAPEX, % |
|
|
3 321% |
5 102% |
1 912% |
|
6 623% |
|
7 937% |
|
|
CAPEX/Revenue, % |
|
|
18.3% |
27.6% |
3.75% |
0.00% |
1.84% |
|
1.32% |
|
| Arcturus Therapeutics Holdings shareholders |
